Disparities in lung cancer
- PMID: 37202003
- DOI: 10.1016/j.jnma.2023.02.004
Disparities in lung cancer
Abstract
Lung cancer is the second most common cancer and the leading cause of cancer death among men and women in the United States. Despite a substantial decline in lung cancer incidence and mortality across all races in the last few decades, medically underserved racial and ethnic minority populations continue to carry the greatest burden of disease throughout the lung cancer continuum. Black individuals experience a higher incidence of lung cancer due to lower rates of low-dose computed tomography screening, which translate into advanced disease stage at diagnosis and poorer survival outcomes compared with White individuals. With respect to treatment, Black patients are less likely to receive gold standard surgery, have access to biomarker testing or high-quality treatment compared with White patients. The reasons for those disparities are multifactorial and include socioeconomic (eg, poverty, lack of health insurance, and inadequate education), and geographic inequalities. The objective of this article is to review the sources of racial and ethnic disparities in lung cancer, and to propose recommendations to help address them.
Keywords: Lung cancer; Racial and ethnic disparities; Screening.
Copyright © 2023. Published by Elsevier Inc.
Conflict of interest statement
Conflict of interest Narjust Duma, MD, Advisory Board: AstraZeneca, Janssen, Pfizer Inc; Nathaniel Evans III, MD, Consultant: Intuitive Surgical (Proctor); Edith Mitchell, MD, MACP, FCPP, FRCP, Consultant: AstraZeneca, Bristol Myers Squibb, Genentech, Merck & Co., Inc., Pfizer Inc., Taiho Oncology, Inc.; Clinical Research: Amgen, Genentech
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
